Clinical Laboratory reimbursement alerts

The upcoming public meeting for the Clinical Laboratory Fee Schedule will focus on new and reconsidered test codes, which could significantly influence payment amounts for laboratories. Stakeholders a

The upcoming public meeting will impact the reimbursement strategies for new and revised clinical diagnostic laboratory test codes under the Clinical Laboratory Fee Schedule (CLFS) for 2026. Stakehold

The upcoming public meeting on June 25, 2024, will address new and reconsidered clinical diagnostic laboratory test codes impacting the Clinical Laboratory Fee Schedule for 2025. Stakeholders will hav

The public meeting focuses on establishing payment amounts for new and revised laboratory test codes under the Clinical Laboratory Fee Schedule, potentially impacting reimbursement rates for diagnosti

The proposed local coverage determination (LCD) for histochemical and immunohistochemical stains could impact billing by clarifying guidelines and coverage for these laboratory tests. This may lead to

The proposed Local Coverage Decision regarding special histochemical and immunohistochemical stains may impact billing practices for laboratories. Providers should ensure that they have appropriate do

The proposed LCD by Palmetto GBA for molecular testing related to solid organ allograft rejection could impact billing significantly by establishing specific criteria for coverage. This may lead to in

The proposed Local Coverage Determination (LCD) for molecular testing related to solid organ allograft rejection could significantly influence billing practices for relevant tests. With proper coding,

The updated CLIA fees will impact reimbursement for clinical laboratory services, potentially increasing costs for laboratories while ensuring sustainable funding for the program. Enhanced fees for fo

The new MolDX coverage for hereditary transthyretin amyloidosis testing will provide reimbursement pathways for diagnostic molecular tests, benefiting patients and providers through enhanced testing a

The effective date of the LCD for Ionized Calcium indicates changes in the coverage and billing practices for this test. This may lead to adjustments in claims processing and reimbursement rates, requ

The implementation of the new LCD on Vitamin D Assay Testing will impact billing practices significantly. Providers will need to familiarize themselves with the new guidelines to ensure appropriate re

The introduction of the new LCD for Vitamin D Assay Testing by Noridian may affect billing practices, ensuring that healthcare providers follow updated guidelines for testing reimbursement. As a resul

The recent LCD regarding Vitamin D assay testing by Noridian may impact billing practices significantly, especially in terms of coverage and reimbursement rates. Providers must ensure compliance with

The introduction of the MolDX: Molecular Diagnostic Tests policy will significantly impact billing practices for molecular diagnostics, potentially leading to changes in reimbursement rates. It is cru

The LCD on Vitamin D Assay Testing by WPS may impact billing by clarifying coverage criteria which may lead to more denials for tests not meeting the outlined requirements. This could require provider

The new LCD for Cystatin C Measurement by Noridian, effective September 11, 2025, may impact billing practices for clinical laboratories. Providers will need to ensure compliance with the guidelines o

The introduction of new guidelines for Special Histochemical and Immunohistochemical Stains by Noridian may impact billing practices significantly. Providers should ensure they are familiar with the n

The new LCD on Special Histochemical and Immunohistochemical Stains is likely to impact lab billing practices significantly by specifying the criteria for coverage. Providers should ensure that their

The upcoming Local Coverage Determination for Cystatin C Measurement may impact billing practices significantly as of its effective date in February 2025. Providers will need to ensure they understand

The introduction of the MolDX Pharmacogenomics Testing LCD by Palmetto GBA may significantly impact the billing for genetic testing services within the specified effective date. Providers must ensure

The new LCD for Pharmacogenomics Testing by WPS may lead to supports compliance with updated rates practices for these tests. Providers will need to ensure that they meet the updated criteria to avoid claim de

The addition of coverage for Coenzyme Q10 (CoQ10) may lead to increased lab compliance updates for outpatient labs. Proper coding and documentation are essential to ensure reimbursement and complia

The new LCD for Serum Magnesium by Noridian could impact billing by necessitating updated coding practices and justification for claims related to serum magnesium levels. Providers should prepare for

The introduction of the MDS FISH LCD by Noridian is expected to impact billing processes significantly starting from the effective date of October 23, 2025. Providers will need to familiarize themselv

The LCD for Serum Magnesium under Noridian may lead to changes in reimbursement for associated tests. Practitioners should ensure compliance with the new guidelines to avoid revenue impact.

The addition of Coenzyme Q10 (CoQ10) to the lab test offerings under Noridian could enhance compliance updates for clinicians addressing certain conditions where CoQ10 is indicated. Providers shoul

The introduction of MolDX: Pharmacogenomics Testing will significantly impact billing processes starting October 23, 2025. Providers must stay updated on the specific coding and coverage criteria to e

The introduction of the MDS FISH LCD by Noridian may affect billing processes, particularly for laboratories performing MDS-related testing. Providers should familiarize themselves with the specific r

The implementation of LCD BDX-XL2 by Noridian may require changes in billing practices for affected services. Providers need to ensure they are coding accurately to comply with the new coverage guidel

The new LCD for Flow Cytometry by Noridian, effective from 11/06/2025, may affect billing practices by requiring specific documentation and justification for tests performed. Providers will need to st

The implementation of the LCD for Flow Cytometry by Noridian may significantly affect billing practices for laboratories. Providers must ensure that they are accurately coding and documenting services

The introduction of Cystatin C Measurement coverage could potentially supports compliance with updated rates for laboratories offering this test, impacting overall billing processes among providers. It may encou

The implementation of the MDS FISH LCD by Palmetto GBA may affect reimbursement levels for certain diagnostic tests, potentially impacting overall billing practices. Providers should prepare for chang

The new LCD for Vitamin D assay testing enacted by Palmetto GBA may impact billing processes for providers. They should prepare to implement updated codes and guidelines on or after the effective date

The new LCD for MDS FISH from CGS may impact billing for genetic testing services. Providers will need to familiarize themselves with the updated guidelines to ensure compliance and appropriate reimbu

The new MolDX coverage by Noridian will impact billing for molecular diagnostic tests significantly. Starting from February 2026, providers must ensure compliance with the updated guidelines to maximi

The implementation of the MolDX for hereditary transthyretin amyloidosis will have significant implications for billing processes, particularly in the realm of genetic testing reimbursements. Faciliti

The new LCD from Noridian regarding repeat germline testing may necessitate adjustments in billing practices to ensure compliance with updated coverage guidelines. Providers should assess their existi

The implementation of the MolDX policy by Noridian allows for the coverage of additional molecular diagnostic tests, which may enhance patient care but can also introduce complexity in billing. Provid

The implementation of the MolDX LCD on Next-Generation Sequencing for myeloid malignancies requires billing team review-developed tests. This change is expected to improve reimbursemen

The implementation of the MolDX: Pharmacogenomics Testing LCD is set to impact billing practices significantly, requiring healthcare providers to adapt to new coverage and documentation requirements.

The updated Local Coverage Determination (LCD) on special histochemical and immunohistochemical stains may impact billing practices by outlining specific coding and documentation requirements. Provide

The implementation of the Flow Cytometry LCD by CGS has implications for billing practices starting March 5, 2026. Providers will need to ensure they are compliant with the new guidelines to avoid cla

The introduction of the MolDX coverage for pharmacogenomics testing could significantly impact billing practices, especially for laboratories that offer genetic testing services. Providers will need t

The new LCD for hereditary transthyretin amyloidosis will have a significant impact on billing practices for laboratories performing molecular testing. Providers will need to ensure they are compliant

The final LCD L36805 details coverage guidelines for special histochemical and immunohistochemical stains, effective April 30, 2026. Providers in the specified states should review this LCD to ensure

The final LCD L35000 focuses on Molecular Pathology Procedures and is set to take effect on July 15, 2026. Providers in relevant states should prepare for potential billing changes associated with thi

The July 2026 Quarterly Update to the Clinical Laboratory Fee Schedule (CLFS) introduces changes that may affect the billing procedures for clinical laboratory services. Billing teams need to review t

2026 Clinical Laboratory Fee Schedule — official CMS fee schedule. Effective January 1, 2026.